ArticleScientific reports2018
The amino acid selected for generating mutant TbpB antigens defective in binding transferrin can compromise the in vivo protective capacity.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Development of a cross-protective subunit cocktail vaccine against diverse serotypes of Glaesserella parasuis infection in pigs.Veterinary research · 2026Article
- Temporal Dynamics of T Cell Immunity Induced by TbpBVeterinary sciences · 2026Article
- Structure-based engineering of a nutrient acquisition protein enhances neutralizing antibodies and protection for the development of a gonococcal vaccine.bioRxiv : the preprint server for biology · 2025Article
- Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeae.NPJ vaccines · 2025Article
- Research progress onFrontiers in veterinary science · 2025Review
- TbpB-based oral mucosal vaccine provides heterologous protection against Glässer's disease caused by different serovars of Spanish field isolates of Glaesserella parasuis.Porcine health management · 2024Article
- Virulence and Antimicrobial Resistance Characterization ofAntibiotics (Basel, Switzerland) · 2024Article
- In Vivo Validation of Novel SyntheticVaccines · 2023Article
- Pili Subunit PilA Contributes to the Cytoadhesion ofApplied and environmental microbiology · 2023Article
- Screening of linear B-cell epitopes and its proinflammatory activities ofFrontiers in cellular and infection microbiology · 2023Article
- Targeting bacterial transferrin and lactoferrin receptors for vaccines.Trends in microbiology · 2022Review
- TbpBPathogens (Basel, Switzerland) · 2022Article
- Insights from targeting transferrin receptors to develop vaccines for pathogens of humans and food production animals.Frontiers in cellular and infection microbiology · 2022Article
- Development of a non-biased, high-throughput ELISA for the rapid evaluation of immunogenicity and cross-reactivity.Journal of immunological methods · 2021Article
- Tildipirosin: An effective antibiotic against Glaesserella parasuis from an in vitro analysis.Veterinary and animal science · 2020Article
- Evaluation of the recombinant proteins RlpB and VacJ as a vaccine for protection against Glaesserella parasuis in pigs.BMC veterinary research · 2020Article
- Hybrid Antigens Expressing Surface Loops of ZnuD FromFrontiers in immunology · 2020Article
- Proof of Concept for Prevention of Natural Colonization by Oral Needle-Free Administration of a Microparticle Vaccine.Frontiers in immunology · 2020Article
- New Pathological Lesions Developed in Pigs by a "Non-virulent" Strain ofFrontiers in veterinary science · 2020Article
- Molecular serotyping of clinical strains ofPeerJ · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Haemophilus parasuis is the causative agent of the Glässer's disease (GD), one of the most important bacterial diseases that affect young pigs worldwide. GD prevention based on vaccination is a major concern due to the limited cross-protection conferred by the inactivated whole cell vaccines used currently. In this study, vaccines based on two mutant recombinant proteins derived from transferrin binding protein B of H. parasuis (Y167A-TbpB and W176A-TbpB) were formulated and evaluated in terms of protection against lethal challenge using a serovar 7 (SV7) H. parasuis in a high susceptibility pig model. Our results showed that H. parasuis strain 174 (SV7) is highly virulent in conventional and colostrum-deprived pigs. The Y167A-TbpB and W176A-TbpB antigens were immunogenic in pigs, however, differences in terms of antigenicity and functional immune response were observed. In regard to protection, animals immunized with Y167A-TbpB antigen displayed 80% survival whereas the W176A-TbpB protein was not protective. In conjunction with previous studies, our results demonstrate, (a) the importance of testing engineered antigens in an in vivo pig challenge model, and, (b) that the Y167A-TbpB antigen is a promising antigen for developing a broad-spectrum vaccine against H. parasuis infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.